The White House psychedelics executive order accelerates research, clinical trials and “Right to Try” access for drugs like psilocybin, MDMA and ibogaine.
The White House psychedelics executive order accelerates research, clinical trials and “Right to Try” access for drugs like psilocybin, MDMA and ibogaine.
